EP1137412A4 - Composes heterocycliques azotes substitues et leur utilisation therapeutique - Google Patents

Composes heterocycliques azotes substitues et leur utilisation therapeutique

Info

Publication number
EP1137412A4
EP1137412A4 EP99965946A EP99965946A EP1137412A4 EP 1137412 A4 EP1137412 A4 EP 1137412A4 EP 99965946 A EP99965946 A EP 99965946A EP 99965946 A EP99965946 A EP 99965946A EP 1137412 A4 EP1137412 A4 EP 1137412A4
Authority
EP
European Patent Office
Prior art keywords
heterocyclic compounds
therapeutic uses
substituted nitrogen
nitrogen heterocyclic
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99965946A
Other languages
German (de)
English (en)
Other versions
EP1137412A2 (fr
Inventor
Jacob Szmuszkovicz
Ciaran M Regan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Dublin
American Biogenetic Sciences Inc
Original Assignee
University College Dublin
American Biogenetic Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Dublin, American Biogenetic Sciences Inc filed Critical University College Dublin
Publication of EP1137412A2 publication Critical patent/EP1137412A2/fr
Publication of EP1137412A4 publication Critical patent/EP1137412A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99965946A 1998-12-11 1999-12-01 Composes heterocycliques azotes substitues et leur utilisation therapeutique Withdrawn EP1137412A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11183998P 1998-12-11 1998-12-11
US111839P 1998-12-11
PCT/US1999/028374 WO2000033788A2 (fr) 1998-12-11 1999-12-01 Composes heterocycliques azotes substitues et leur utilisation therapeutique

Publications (2)

Publication Number Publication Date
EP1137412A2 EP1137412A2 (fr) 2001-10-04
EP1137412A4 true EP1137412A4 (fr) 2002-04-03

Family

ID=22340712

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99965946A Withdrawn EP1137412A4 (fr) 1998-12-11 1999-12-01 Composes heterocycliques azotes substitues et leur utilisation therapeutique

Country Status (4)

Country Link
EP (1) EP1137412A4 (fr)
AU (1) AU2160900A (fr)
CA (1) CA2355296A1 (fr)
WO (1) WO2000033788A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2819511A1 (fr) * 2001-01-18 2002-07-19 Servier Lab Nouveaux composes azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004002483A1 (fr) * 2002-06-27 2004-01-08 Actelion Pharmaceuticals Ltd 3- et 4- aminomethylpiperidines substituees utilisees comme beta-secretase dans le traitement de la maladie d'alzheimer
WO2005108359A1 (fr) * 2004-05-06 2005-11-17 Pfizer Inc. Nouveaux composes de derives de proline et de morpholine
JP2006143667A (ja) * 2004-11-22 2006-06-08 Ube Ind Ltd ピペコリン酸アミド誘導体及び抗菌剤
WO2008003697A1 (fr) 2006-07-06 2008-01-10 Glaxo Group Limited N-phenylmethyl -5-oxo-proline-2-amides substitués tenant lieu d'antagonistes du récepteur p2x7 et procédés d'utilisation
WO2009074518A1 (fr) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinaisons formées de modulateurs au prolinamide du récepteur p2x7 et d'autres agents thérapeutiques
US8629157B2 (en) 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
CN110240557B (zh) 2018-03-08 2023-05-09 广东东阳光药业有限公司 吡咯烷酰胺衍生物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508880A (en) * 1974-12-18 1978-04-26 Synthelabo 2-methoxy-benzamide derivatives
EP0296560A2 (fr) * 1987-06-22 1988-12-28 Eisai Co., Ltd. Pipéridines 1,4-substituées comme inhibiteurs de l'acétylcholinestérase et leur utilisation dans le traitement de la maladie d'Alzheimer
JPH02104568A (ja) * 1988-06-22 1990-04-17 Yoshitomi Pharmaceut Ind Ltd 神経成長因子産生促進作用剤
US5053548A (en) * 1989-02-08 1991-10-01 Otsuka Pharmaceutical Company, Ltd. Biphenyl derivative composition for nerve cell degeneration repairing or protective agent and process for preparing a phenyl derivative contained in the composition
US5446147A (en) * 1992-04-03 1995-08-29 Trustees Of The University Of Pennsylvania Fluorinated and iodinated dopamine agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3367104B2 (ja) * 1992-04-13 2003-01-14 藤沢薬品工業株式会社 抗菌剤としての置換された３−ピロリジニルチオ−カルバペネム化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508880A (en) * 1974-12-18 1978-04-26 Synthelabo 2-methoxy-benzamide derivatives
EP0296560A2 (fr) * 1987-06-22 1988-12-28 Eisai Co., Ltd. Pipéridines 1,4-substituées comme inhibiteurs de l'acétylcholinestérase et leur utilisation dans le traitement de la maladie d'Alzheimer
JPH02104568A (ja) * 1988-06-22 1990-04-17 Yoshitomi Pharmaceut Ind Ltd 神経成長因子産生促進作用剤
US5053548A (en) * 1989-02-08 1991-10-01 Otsuka Pharmaceutical Company, Ltd. Biphenyl derivative composition for nerve cell degeneration repairing or protective agent and process for preparing a phenyl derivative contained in the composition
US5446147A (en) * 1992-04-03 1995-08-29 Trustees Of The University Of Pennsylvania Fluorinated and iodinated dopamine agents

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BARLOCCO, D. ET AL: "Monocyclic Analogues of the m-Opioid Antagonist 3,8-Diazabicyclo-[3.2.1]octanes: Synthesis Modeling and Activities", TETRAHEDRON, vol. 51, no. 42, 1995, pages 11547 - 11556, XP001026295 *
CHANDRAKUMAR, N. S. ET AL.: "Preparation and Opioid Activity of Analogues of the Analgesic Dipeptide 2,6-Dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide", J. MED. CHEM., vol. 35, no. 2, 1992, pages 223 - 233, XP001026297 *
COREY, E. J.; LINK, J. O.: "A Catalytic Enantioselective Synthesis of Denopamine, a Useful Drug for Congestive Heart Failure", J. ORG. CHEM, vol. 56, no. 1, 1991, pages 442 - 444, XP001055628 *
DEHMLOW, E. V. ET AL: "Revisiting optically active quaternary derivatives made from prolinol as phase transfer catalysts", TETRAHEDRON ASYMMETRY, vol. 9, no. 13, 1998, pages 2235 - 2244, XP004131368 *
MORIE, T. ET AL: "Ring Expansion of Nitrogen-containing Chloromethylheteroalicycles via Aziridinium Intermediates", J. CHEM. SOC. PERKIN TRANS. I, vol. 18, 1994, pages 2565 - 2570, XP001055909 *
O'NEIL I A ET AL: "The Highly Stereoselective Formation of Pipecolic Acid N-Oxide and Related Derivatives", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 38, no. 32, 1 August 1997 (1997-08-01), pages 5731 - 5734, XP004085745, ISSN: 0040-4039 *
PATENT ABSTRACTS OF JAPAN vol. 014, no. 310 (C - 0736) 4 July 1990 (1990-07-04) *
See also references of WO0033788A3 *
ZHAO S ET AL: "SYNTHESES OF 1,2-DIAMINO AND 1,2-AMINOALCOHOL DERIVATIVES IN THE PIPERIDINE AND PYRROLDINE SERIES AS ANTI-AMNESIC AGENTS", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 7, 1999, pages 1647 - 1654, XP002928878, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
WO2000033788A2 (fr) 2000-06-15
EP1137412A2 (fr) 2001-10-04
AU2160900A (en) 2000-06-26
CA2355296A1 (fr) 2000-06-15
WO2000033788A3 (fr) 2000-10-19

Similar Documents

Publication Publication Date Title
EP0940400A4 (fr) Nouveaux composes d'amide heterocycliques et leur utilisation a des fins medicinales
HK1040995A1 (zh) 二氧喹啉化合物及其醫藥用途
EP1223932A4 (fr) Composes et methodes
EP1146790A4 (fr) Composes et procedes
IL130851A0 (en) Heterocyclic compounds and their use for inhibiting beta-amyloid peptide
EP0988295A4 (fr) Piperidines a substitution heterocyclique et utilisations de ces dernieres
HK1053657A1 (en) Novel heterocyclic compounds and salts thereof andmedicinal use of the same
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
EP1194147A4 (fr) Derives d'arylthiazolidinedione et d'aryloxazolidinedione
EP1137412A4 (fr) Composes heterocycliques azotes substitues et leur utilisation therapeutique
ZA9811346B (en) Substituted heterocyclic benzocycloalkenes and their use as an analgesic
GB9824160D0 (en) Heterocyclic compounds and their therapeutic use
EP1229913A4 (fr) 1-benzazepines substituees et leurs derives
EP1032559A4 (fr) Derives d'amino-alkylphenols et composes associes
EP1112250A4 (fr) Composes therapeutiques et methodes afferentes
HK1044773A1 (zh) 雜環n-丙酮基苯甲酰胺以及它們作為殺菌劑的使用
GB9820768D0 (en) Heterocyclic compounds and their therapeutic use
GB9819505D0 (en) Heterocyclic compounds and their therapeutic use
EP1150967A4 (fr) Composes et methodes therapeutiques
GB9713240D0 (en) Heterocyclic compounds and their therapeutic use
GB9930199D0 (en) Heterocyclic compounds and their therapeutic use
AU9646998A (en) Heterocyclic compounds and use thereof
GB9424258D0 (en) Nitrogen heterocyclic compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010618

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020219

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/40 A, 7A 61K 31/445 B, 7C 07D 207/16 B, 7C 07D 207/08 B, 7C 07D 207/09 B, 7C 07D 211/22 B, 7C 07D 211/26 B, 7C 07D 211/60 B, 7C 07D 223/12 B, 7A 61K 31/55 B, 7A 61P 25/28 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020507